Target intelligence / Profile preview

ATP synthase (mitochondrial F1F0 complex) (ATP synthase (Complex V))

Target
ATP synthase (Complex V)
Molecular classification
Enzyme, Mitochondrial respiratory complex, Rotary ATPase, Proton transporter
01

Overview

ATP synthase (Complex V) is a multi-subunit rotary enzyme embedded in the inner mitochondrial membrane where it catalyzes the synthesis of ATP from ADP and inorganic phosphate, powered by the proton-motive force generated by the respiratory chain complexes. Structurally, it consists of the F1 catalytic domain protruding into the mitochondrial matrix and the membrane-embedded Fo domain, functioning together through a rotary mechanism to convert electrochemical energy into chemical energy. Inhibitors of ATP synthase are under investigation for multiple therapeutic areas, particularly cancer (to target the metabolic vulnerabilities of malignant cells), neurodegenerative diseases (due to ATP synthase dysfunction or modification in disease pathogenesis), and infectious diseases. ATP synthase activity and modification are disease-biomarkers, and one or more subunits may be specifically targeted or dysregulated in various conditions[1][3][4][5][6][8].

Other names
F1F0-ATPaseComplex Vmitochondrial ATP synthaseH+-ATPase
02

Mechanism of action

Inhibition of proton translocation or rotary catalysis, blocking ATP synthesis; Non-competitive inhibition of F1-ATPase activity; Promotion of mitochondrial reactive oxygen species (ROS) (as a result of ATP synthase inhibition); Modulation of downstream energy-dependent cell signaling (e.g., AMPK/mTOR via J147).

03

Biological functions

ATP synthesis from ADP and inorganic phosphateMaintenance of cellular energy statusCoupling of oxidative phosphorylationRegulation of mitochondrial membrane potential
04

Disease associations

Neurodegenerative diseases (e.g., Alzheimer's, Parkinson's, Huntington’s disease)Cancer progression and metastasisMitochondrial diseases and oxidative phosphorylation disordersAgingCardiovascular diseases
05

Safety considerations

Inhibition may compromise cellular energy homeostasis in non-target tissuesMitochondrial toxicity: cell viability depends on preserved ATP synthesisRisk of off-target toxicity in tissues with high energy demands
06

Interacting drugs

Bedaquiline (targets gamma subunit, FDA-approved)

5 more in the full profile.

07

Biomarkers

ATP5F1C expression as a biomarker for metastasis and prognosis in cancerATP synthase subunit modifications (e.g., HNE-oxidation of alpha subunit in AD)

Beyond the preview

Go deeper on ATP synthase (mitochondrial F1F0 complex) (ATP synthase (Complex V)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP synthase (mitochondrial F1F0 complex) (ATP synthase (Complex V)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call